KURA ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.71 USD | -0.29% |
|
+0.39% | +44.02% |
| May. 02 | Transcript : Kura Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
| May. 02 | Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechTroy Wilson (Executives)All right. Good morning, everyone. Thank you for joini...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
20.71
USD
Average target price
30.25
USD
Spread / Average Target
+46.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.02% | 1.58B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| -0.26% | 22.25B | |
| -13.14% | 22.09B | |
| -7.89% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Transcript : Kura Oncology, Inc. - Special Call